Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Ceftriaxone

Ceftriaxone

Third-generation cephalosporin (IV/IM)

MeningitisCAPGonorrheaq24hΞ²-lactam

Indication

Bacteremia β€’ CAP β€’ meningitis (combo) β€’ pyelonephritis β€’ SSTI β€’ gonorrhea (local resistance)

At a glance

INDICATIONS (CORE USE)

Serious gram-negative + many strep infections; meningitis (with adjunct per guideline); gonorrhea (check resistance) β€” avoid Ca-containing fluids in same line / neonatal cautions.

ADULT DOSE (STANDARD)

1–2 g IV/IM q24h (many indications); meningitis higher per protocol; some q12h severe

MAX DOSE

Adult ~4 g/day (4 g q24h not universal β€” follow local max); neonates contraindicated in some contexts

Route

IV, IM

PEDIATRIC DOSE

50–100 mg/kg/day IV/IM divided (meningitis max doses per guideline)

Do not miss

Must-not-miss safety points

Major warning

- Ξ²-lactam anaphylaxis - **Neonatal kernicterus / bilirubin displacement** β€” avoid in hyperbilirubinemic neonates per labeling - **Ca precipitation** β€” do not reconstitute/mix with Ringer’s lactate or Ca-containing solutions in same line - ESBL producers β†’ treatment failure despite in vitro labels β€” know local epidemiology - Gallbladder sludge/pseudolithiasis with prolonged use

Indications

USE IF: Serious infections when ceftriaxone-susceptible organisms likely; meningitis as part of regimen; gonorrhea only if local susceptibility supports. AVOID IF: Neonates per product warnings; concurrent IV calcium compatibility issues; suspected ceftriaxone-resistant gonorrhea.

Primary

  • Community-acquired pneumonia (inpatient / severe outpatient per guideline)
  • Pyelonephritis / complicated UTI (susceptible organism)
  • Bacteremia due to susceptible gram-negatives / streptococci (source control essential)
  • Meningitis: part of combination regimen per age/pathogen guideline

Secondary

  • Acute otitis media / sinusitis severe systemic features (IV route)
  • Lyme carditis / meningitis (ID-guided)

Other

  • Some STI regimens where local gonococcal resistance allows

Dosing

STANDARD (ADULT PO)

1 g IV q24h (many moderate infections); 2 g IV q24h severe

ADULT DOSE

1–2 g IV/IM q24h; some severe infections q12h Meningitis: adult often 2 g IV q12h (with other agents per guideline)

PEDIATRIC DOSE

Weight-based per pediatric meningitis/sepsis protocols; avoid in contraindicated neonatal scenarios.

MAX DOSE

Adult commonly cited max 4 g/day β€” institution may cap lower.

Practical Note

Compatible diluents only; Y-site check with Ca-containing products.

Warnings

Clinical warnings

  • **Ξ²-lactam allergy β€” immediate** (anaphylaxis, angioedema, bronchospasm, hypotension) β†’ **avoid** this agent; use non–β-lactam alternative
  • **Ξ²-lactam allergy β€” non-severe** (maculopapular rash without systemic anaphylaxis features) β†’ **caution**; risk/benefit + allergy/ID pathway; graded challenge or test dose **only** per protocol β€” do not dismiss automatically
  • **Neurotoxicity:** encephalopathy, confusion, myoclonus, seizures β€” **higher risk with CKD, elderly, dose accumulation** (notably cefepime, carbapenems, high-dose penicillins)
  • New CNS symptoms + renal impairment on IV Ξ²-lactam β†’ **hold dose**, check levels/exposure, rule out other causes
  • Immune hemolytic anemia (rare)
  • Pancreatitis / biliary pseudolithiasis with prolonged therapy
  • C. diff

Adverse effects

  • diarrhea
  • rash
  • biliary sludge
  • phlebitis

Contraindications

  • Neonates (0–28 days) receiving IV calcium-containing solutions β€” precipitation risk (label-specific)
  • Hyperbilirubinemic neonates β€” per product contraindication

Drug interactions

  • Warfarin β†’ INR changes possible
  • IV calcium compatibility β€” critical

Special populations

Pediatrics

50–100 mg/kg/day IV/IM divided (meningitis max doses per guideline)

Pregnancy

Pregnancy: generally used when indicated.

Lactation

low risk; monitor infant GI.

Renal impairment

Usually no adjustment as dual elimination; **if combined severe hepatic impairment** β†’ reduce per label. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β‰₯50** β†’ standard interval (per Adult dosing card) - **CrCl 10–50** β†’ extend interval and/or reduce dose (often q12–24h or ↓ dose β€” **product-specific**) - **CrCl <10** β†’ maximal interval extension / dose reduction; **HD: redose post-dialysis** per protocol; AKI β†’ re-estimate CrCl; **neuro signs** β†’ hold/adjust

Hepatic impairment

Severe hepatic failure + renal failure β†’ accumulation risk β€” adjust per monograph.

Elderly

Fall risk; drug–drug interactions; bleeding risk with anticoagulation.

Administration

IV infusion per stability charts; IM deep injection large muscle.

Monitoring

  • Monitor: - ICU or CKD β†’ **creatinine daily** β†’ underdosing in AKI vs accumulation / **neurotoxicity** if not adjusted - New confusion / myoclonus / seizures + renal impairment on IV Ξ²-lactam β†’ **hold dose** β†’ evaluate encephalopathy - Serious GNR infection β†’ extended-infusion / pharmacy optimization per protocol - Repeat cultures / clinical lactate clearance in sepsis - LFTs / RUQ symptoms if prolonged IV ceftriaxone - Gonorrhea: test-of-cure / resistance surveillance per public health
  • Recheck: - No clinical improvement at 48–72h β†’ reassess diagnosis, resistance, source control, and drug interactions - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**Life-threatening (first):** **CNS toxicity** β€” seizures, encephalopathy, agitation, myoclonus, coma (**↑ CKD, elderly, accumulation**; cefepime, carbapenems, high-dose penicillins). **Allergic:** anaphylaxis / angioedema (separate pathway). **Secondary:** nausea/vomiting/diarrhea mainly with acute massive **oral** co-ingestion or local infusion reaction.

Immediate Actions

Stop Ξ²-lactam β†’ ABCs β†’ **seizure precautions**; benzos if seizures; check renal function / dose vs CrCl; anaphylaxis β†’ epinephrine + ACLS

Antidote

No specific antidote; treat complications (e.g. anaphylaxis β†’ epinephrine per ACLS)

Decontamination

Stop infusion; recent large PO load β†’ charcoal if protected airway + early presentation

Escalation

Status epilepticus, coma, refractory seizures β†’ **ICU**; **severe CNS toxicity or AKI with accumulation β†’ consider hemodialysis** for dialyzable agents β€” nephrology + pharmacy; persistent anaphylaxis β†’ ICU

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Workhorse IV third-gen β€” **q24h** convenience. **Never** mix with IV calcium. Neonatal/bilirubin rules are real.

Clinical pearls

Stewardship: shortest effective duration. De-escalation: oral options when stable. Meningitis always combination + dexamethasone per age. *Stewardship (all antimicrobials):* Empiric choice β†’ syndrome severity + **local antibiogram**; shortest effective course.

Stewardship & safety

  • Ca compatibility
  • Neonate cautions
  • Biliary sludge long course

Pharmacokinetics

Long TΒ½ (~6–9 h) enables q24h; protein binding high; biliary + renal elimination.

Mechanism of action

Third-gen cephalosporin β€” PBP affinity for many gram-negatives + streptococci.

Common brand names

Saudi Arabia

Rocephin, Triaxone, Oframax

Global

(placeholder β€” verify local formulary)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Empiric choice β†’ tie to syndrome, severity, and local antibiogram β€” not habit.
  • IV β†’ PO step-down when oral bioavailability and susceptibility allow.
  • Do not use antibiotics for uncomplicated viral illness β€” stewardship.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling

Do not miss

  • Uncomplicated viral URI/bronchitis β†’ antibiotics rarely indicated
  • Narrow or stop when susceptibilities + clinical stability allow
  • Ca line precipitation.
  • Gonorrhea resistance β€” verify local guidance.
  • ESBL risk β†’ failure despite β€˜sensitive’ lab printouts in some cases.
  • Ca compatibility
  • Neonate cautions
  • Biliary sludge long course